ABPI-BIA submission to MHRA consultation on EU Exit 'no deal' contingency legislation for the regulation of medicines and medical devices

The ABPI and BIA have worked together to develop this joint submission to the MHRA consultation. We have provided our members’ views on how the MHRA’s legislation and regulatory processes would have to be modified in the event of the UK not securing a deal with the EU after the UK’s exit, with no Implementation Period. This consultation covers no-deal proposals on medicines, clinical trials and medical devices.
TAGS
- Brexit
Last modified: 20 September 2023
Last reviewed: 20 September 2023